Clarifying the legal landscape of psilocybin regulation: A medico-legal perspective
Drug Science Policy and Law April 1, 2025 1 citation
No Summary
Drug Science Policy and Law
ISSN 2050-3245
31 papers in the library · 932 citations · publishing 2015-2026
Papers
Do undergraduates’ views of psychedelics relate to the context for psychedelic use?
Drug Science Policy and Law March 1, 2025 Dan Petrovitch, Jason van Allen, Sean M. Mitchell et al. 1 citation
Psychedelic-naïve undergraduates generally hold similar views of psilocybin and LSD across clinical therapy, microdosing, and naturalistic contexts, making only limited distinctions. When differences did appear, participants viewed clinical use most positively, followed by microdosing, then naturalistic use. The findings suggest that young adults may benefit from education about the varying safety, efficacy, and legality of psychedelics across contexts, especially given their potential influence on drug policy.
The medical sociological and social epidemiological psychedelics paradigm (MSSEPP)
Drug Science Policy and Law November 1, 2025 S. Viña
A new theoretical framework, the medical sociological and social epidemiological psychedelics paradigm (MSSEPP), is proposed to address ethical concerns, lack of participant diversity, and limitations of the dominant biopsychic model in psychedelic research. MSSEPP integrates medical sociology and social epidemiology to emphasize how social, cultural, structural, and economic conditions together shape health outcomes from psychedelic use. It accounts for indirect and interacting effects across the life-course, often neglected in existing models. The article outlines an agenda to incorporate structural determinants, intersectional stigma, and community-based frameworks into psychedelic science, aiming for a more holistic and ethically grounded orientation for research, clinical design, and policy.
A phenomenological analysis of Fellini's films to understand the effect of LSD therapy on his creativity
Drug Science Policy and Law January 1, 2023 Antonio Metastasio, Silvio Mignogna, Riccardo Paci et al.
LSD, when used under therapeutic guidance, enhanced the filmmaking creativity of Federico Fellini by altering his perception of time, space, body, and self. Time in his films flows irregularly with disorienting flashbacks; colors become supernaturally brilliant and detached from objects; sounds emerge independently from visible sources; and human bodies appear deformed, grotesque, and caricatural. The boundaries between dream and reality collapse. These changes made his films so distinctive that the adjective 'felliniesque' was coined.
Can ayahuasca reduce inattention, hyperactivity and impulsivity? A pilot study
Drug Science Policy and Law January 1, 2023 WaiFung Tsang, Simon Ruffell, Nigel Netzband et al.
Adults who attended ayahuasca retreats in Peru reported fewer symptoms of inattention, hyperactivity, and impulsivity afterward, regardless of retreat length or number of ceremonies. In an exploratory pilot study, 49 adults completed the Adult ADHD Self-Report Scale before and after retreats lasting 8 days to 4 weeks. Scores for inattention, hyperactivity/impulsivity, and total symptoms all dropped significantly. Only four participants had a prior ADHD diagnosis. The findings suggest ayahuasca may be associated with reductions in core ADHD features, but controlled trials are needed to confirm causality.
Italian psychedelic therapies of the past century: An historical overview
Drug Science Policy and Law January 1, 2023 Adriana D’arienzo, Giorgio Samorini
Italy conducted the most clinical studies on psilocybin and lysergic acid amide (LSA) in the twentieth century, and humans first received a high dose of 500 mcg of lysergic acid diethylamide (LSD) there. The most successful Italian studies used psilocybin intravenously at 3 mg every second or third day, alternated with placebo, to treat depressive states. LSD and psilocybin also showed promise for treating neurosis. Italian psychiatrists contributed to theoretical debates on the psychotomimetic paradigm and the distinction between primary and secondary effects of psychedelics.